Health
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
At ObesityWeek® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, including hypertension and systemic inflammation.1-3 The results from the post hoc analysis of REDEFINE 1, exploring the CV risk reduction potential of investigational CagriSema, were also simultan
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications to reduce or stop their medication1","length":232,"tagName":"p"}]},{"val":[{"type":"text","content":"CagriSema treatment demonstrated a nearly 70% reduction in a key inflammatory marker associated with increased cardiovascular risk2","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Data showed that fewer people on CagriSema were at intermediate-to-high risk of developing atherosclerotic cardiovascular disease (ASCVD) within the next 10 years3","length":163,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":526,"olType":false},{"type":"text","content":"PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 6, 2025 /PRNewswire/ -- At ObesityWeek® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, including hypertension and systemic inflammation.1-3 The results from the post hoc analysis of REDEFINE 1, exploring the CV risk reduction potential of investigational CagriSema, were also simultaneously published in Hypertension.1","length":613,"tagName":"p"},{"type":"text","content":"With CagriSema treatment, systolic blood pressure was reduced by -10.9 mmHg over 68 weeks (versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo).* This reduction was seen regardless of BMI (less than versus greater than or equal to 35 kg/m2). In the CagriSema group, nearly 4 out of 10 people who had been on blood pressure-lowering medication were able to cut down or stop this medication during the trial.1 Exploratory post hoc analyses are hypothesis generating, and further work investigating the clinical validity of these results would be of value.","length":569,"tagName":"p"},{"type":"text","content":""We're very excited by the results of these analyses of CagriSema, which show promising results of combining cagrilintide with the proven significant effects of semaglutide on CV health," said Martin Holst Lange, chief scientific officer and executi...